Atypical small acinar proliferation
| Atypical small acinar proliferation | |
|---|---|
| Synonyms | ASAP |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Usually asymptomatic |
| Complications | Potential precursor to prostate cancer |
| Onset | Typically in older males |
| Duration | Indeterminate |
| Types | N/A |
| Causes | Unknown |
| Risks | Age, family history of prostate cancer |
| Diagnosis | Prostate biopsy, histopathology |
| Differential diagnosis | Prostatic intraepithelial neoplasia, prostate cancer |
| Prevention | None specific |
| Treatment | Active surveillance, repeat biopsy |
| Medication | N/A |
| Prognosis | Variable, requires monitoring |
| Frequency | Detected in approximately 5% of prostate biopsies |
| Deaths | N/A |
Atypical Small Acinar Proliferation (ASAP) is a histopathological finding often encountered in prostate biopsies. It is characterized by the presence of small acinar structures with architectural or cytological atypia that is not sufficient to definitively diagnose prostate cancer. The diagnosis of ASAP indicates that there is a suspicious area within the prostate that warrants closer scrutiny, often leading to a recommendation for a repeat biopsy.
Definition and Diagnosis[edit]
ASAP is identified through microscopic examination of prostate tissue, typically obtained via a prostate biopsy. The diagnosis is made when the pathologist observes small acinar units that exhibit some, but not all, of the features required for a diagnosis of prostate cancer. These features may include irregular acinar architecture, nuclear atypia, or perineural invasion. However, the atypical findings are not extensive or definitive enough to conclusively diagnose malignancy.
Clinical Significance[edit]
The identification of ASAP is clinically significant because it is associated with an increased risk of finding prostate cancer on subsequent biopsies. Studies have shown that men with a diagnosis of ASAP have a 20-40% chance of being diagnosed with prostate cancer on a follow-up biopsy, which is significantly higher than the risk associated with a benign biopsy result. Therefore, ASAP serves as a marker indicating the need for close surveillance and often a repeat biopsy to ensure that prostate cancer is not missed.
Management[edit]
The management of patients with ASAP typically involves a discussion of the risks and benefits of various follow-up strategies. Options may include increased surveillance with repeat biopsies, the use of multiparametric MRI to better visualize the area of concern, or molecular testing to assess the risk of cancer. The choice of management strategy should be individualized based on the patient's risk factors, overall health, and preferences.
Controversies and Challenges[edit]
One of the main challenges in the management of ASAP is the variability in its interpretation among pathologists, which can lead to differences in management recommendations. Additionally, the psychological impact of a diagnosis that indicates an increased risk of cancer, but without a definitive diagnosis, can be significant for patients. There is ongoing research aimed at improving the diagnostic accuracy of prostate biopsies and identifying molecular markers that may help to stratify the risk of cancer in patients with ASAP.
Conclusion[edit]
Atypical Small Acinar Proliferation is an important diagnostic category in prostate pathology that signifies an increased risk of prostate cancer. It highlights the need for careful follow-up and often a repeat biopsy to ensure that prostate cancer is not overlooked. As research advances, it is hoped that more precise diagnostic and risk stratification tools will become available to aid in the management of patients with ASAP.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian